-
A WEEK-IN-REVIEW FEATURED REPORT
Role of Raltegravir in HIV-1 Management.
Rokas KE, Bookstaver PB, Shamroe CL,
et al
Ann Pharmacother. 2012
Apr;46(4):578-89.
Abstract
-
Divalent metals and pH alter raltegravir disposition in vitro.
Moss DM, Siccardi M, Murphy M, et al
Antimicrob Agents Chemother.
2012 Mar 26.
Abstract
-
Novel agents for the treatment of HIV-2
infection.
Peterson K, Rowland-Jones S.
Antivir Ther. 2012 Jan
25.
Abstract
-
Diketoacid Inhibitors of HIV-1 Integrase: From
L-708,906 to Raltegravir and Beyond.
Beare KD, Coster MJ, Rutledge PJ.
Curr Med Chem. 2012 Jan
2.
Abstract
-
Rural Residence and Adoption of a Novel HIV
Therapy in a National, Equal-Access Healthcare System.
Ohl M, Lund B, Belperio PS, et
al
AIDS Behav. 2011 Dec 29
Abstract
-
Lack of correlation between UGT1A1*6, *28 genotypes, and plasma
raltegravir concentrations in Japanese
HIV-1-infected patients.
Hirano A, Ikemura K, Takahashi M,
et al
AIDS Res Hum Retroviruses.
2011 Oct 7
Abstract
-
Effect of raltegravir on the total and
unintegrated proviral HIV DNA during raltegravir-based HAART.
Nicastri E, Tommasi C, Abbate I, et al
Antivir Ther.
2011;16(6):797-803.
Abstract
-
FULL-TEXT ARTICLE
Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly
Active Antiretroviral Therapy.
Zhu W, Jiao Y, Lei R, et al
PLoS One.
2011;6(6):e21081
Paper
-
Dynamics of HIV-1 DNA level in highly antiretroviral-experienced
patients receiving raltegravir-based
therapy.
Charpentier C, Piketty C, Laureillard D,
et
al
Eur J Clin Microbiol Infect Dis.
2011 May 11.
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Cell disposition of raltegravir and newer antiretrovirals in
HIV-infected patients:
high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A, Buclin T, Franc C, et al
J Antimicrob Chemother.
2011 Apr 19.
Abstract
-
Raltegravir Concentrations in the Genital Tract of HIV-1
infected Women Treated with a
raltegravir containing Regimen : DIVA 01 study
Clavel C, Peytavin G, Tubiana R,
et al
Antimicrob Agents Chemother.
2011 Mar 28.
Abstract
-
Raltegravir: the first HIV-1 integrase strand
transfer inhibitor in the HIV armamentarium.
Nguyen BY, Isaacs RD, Teppler H, et al
Ann N Y Acad Sci. 2011
Mar;1222(1):83-9.
Abstract
-
Liver tolerance of raltegravir-containing
antiretroviral therapy in HIV-infected patients with chronic
hepatitis C.
Macías J, Neukam K, Portilla J, Iribarren JA, et al
J Antimicrob Chemother.
2011 Mar 10
Abstract
-
Raltegravir use in special populations.
Johnson M.
Eur J Med Res.
2009 Nov 24;14 Suppl 3:43-6.
Abstract
-
Dynamic Escape of Pre-Existing
Raltegravir-Resistant HIV-1 from Raltegravir Selection Pressure.
Codoñer FM, Pou C, Thielen A, et al
Antiviral Res.
2010 Sep 27
Abstract
-
Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed
the 50% Inhibitory Concentration for
Wild-Type HIV-1.
Croteau D, Letendre S, Best BM, et al
Antimicrob Agents Chemother.
2010 Sep 27
Abstract
-
Comparison of the influence of four classes of HIV antiretrovirals on
adipogenic
differentiation: the minimal effect of raltegravir and atazanavir.
Minami R, Yamamoto M, Takahama S,
et al
J Infect Chemother.
2010 Aug 13.
Abstract
-
The Effect of Raltegravir Intensification on Low-level Residual
Viremia in HIV-Infected Patients on
Antiretroviral Therapy: A Randomized Controlled Trial.
Gandhi RT, Zheng L, Bosch RJ, et al
PLoS Med.
2010 Aug 10;7(8
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Time course of total HIV-1 DNA and 2-long-terminal repeat
circles in patients with controlled
plasma viremia switching to a raltegravir-containing regimen.
Delaugerre C, Charreau I, Braun J,
et al
AIDS.
2010 Jul 30.
Abstract
-
Postprandial lipid effects of low-dose ritonavir
vs. raltegravir in HIV-uninfected adults.
Samaras K, Richardson R, Carr A.
AIDS. 2010 Jul
17;24(11):1727-31
Abstract
-
Prevention of HIV Protease Inhibitor-induced Dysregulation of Hepatic
Lipid
Metabolism by Raltegravir via ER stress Signaling Pathways.
Cao R, Hu Y, Wang Y, Gurley EC, et al
|
J Pharmacol Exp Ther.
2010 May 14
Abstract
-
FULL-TEXT ARTICLE
Raltegravir is a potent inhibitor of XMRV, a virus implicated in
prostate cancer and
chronic fatigue syndrome.
Singh IR, Gorzynski JE, Drobysheva D, et al
PLoS One. 2010 Apr
1;5(4):e9948.
Paper
-
FULL-TEXT PDF ARTICLE
Response of a simian immunodeficiency virus (SIVmac251) to
raltegravir: a basis
for a new treatment for simian AIDS and an animal model for
studying lentiviral
persistence during antiretroviral therapy.
Lewis MG, Norelli S, Collins M, et al
Retrovirology.
2010 Mar 16;7(1):21
Paper
-
New therapeutic strategies for raltegravir.
Garrido C, Soriano V, de Mendoza C
.J
Antimicrob Chemother.
2009 Dec 16
Abstract
-
High Concentration of Raltegravir in Semen of HIV-infected Men:
a sub-study of the
EASIER-ANRS 138 trial.
Barau C, Delaugerre C, Braun
J, de Castro N,
et al
Antimicrob Agents Chemother.
2009 Dec 7.
Abstract
-
Implementation of Raltegravir in Routine Clinical Practice: Selection
Criteria for Choosing
This Drug, Virologic Response Rates, and Characteristics of Failures.
Scherrer AU, von Wyl V, Fux CA, et al
J Acquir Immune Defic Syndr.
2009 Oct 16
Abstract
-
The HIV-1 integrase genotype strongly predicts raltegravir
susceptibility but not viral fitness
of primary virus isolates.
Buzón MJ, Dalmau J, Puertas MC,
et al
AIDS. 2009 Sep 16
Abstract
-
Loss of Raltegravir Susceptibility of HIV-1 is Conferred by
Multiple Non-overlapping Genetic Pathways.
Fransen S, Gupta S, Danovich R, et al
J
Virol. 2009 Sep 16.
Abstract
-
A WEEK IN REVIEW FEATURED
REPORT
FULL-TEXT ARTICLE
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
Yilmaz A, Gisslén M, Spudich S, et al
PLoS One. 2009 Sep 1;4(9):e6877.
Paper
-
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract
-
Constraints on the dominant mechanism for HIV viral
dynamics in patients on raltegravir.
Sedaghat AR, Siliciano RF, Wilke CO.
Antivir Ther. 2009;14(2):263-71
Abstract
-
Virological and immunological response in HIV-1-infected patients with
multiple treatment failures
receiving raltegravir and optimized background therapy, ANRS CO3
Aquitaine Cohort.
Wittkop L, Breilh D, Da Silva D, et al
J
Antimicrob Chemother.
2009 Mar 31.
Abstract
-
Raltegravir in the management of HIV-infected patients.
Stellbrink HJ.
Drug Des Devel Ther.
2009 Feb 6;2:281-288
Abstract
-
Potential of integrase inhibitors to deplete HIV reservoirs or
prevent their replenishment
Llibre JM, Martínez-Picado J.
Enferm Infecc Microbiol Clin.
2008 Nov;26 Suppl 12:17-22.
Abstract
-
Role of the new molecules in antiretroviral therapy. Position of
raltegravir.
Arribas JR.
Enferm Infecc Microbiol Clin.
2008 Nov;26 Suppl 12:53-9
Abstract
-
FULL-TEXT PDF ARTICLE
Raltegravir, elvitegravir, and metoogravir: the birth of
"me-too" HIV-1 integrase inhibitors.
Serrao E, Odde S, Ramkumar K, Neamati N.
Retrovirology.
2009 Mar 5;6(1):25.
Paper
Correction: Raltegravir, elvitegravir, and metoogravir: the
birth of "me-too" HIV-1 integrase inhibitors.
Serrao E, Odde S, Ramkumar K, Neamati N.
Retrovirology. 2009
Apr 8;6(1):33.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Raltegravir: The First HIV Type 1 Integrase Inhibitor.
Hicks C, Gulick RM
Clin Infect Dis.
2009 Feb 20.
Abstract
-
Raltegravir and Etravirine Are Active against HIV Type 1 Group
O.
Briz V, Garrido C, Poveda E, et al
AIDS Res Hum Retroviruses. 2009
Abstract
-
Quantitative prediction of human clearance guiding the
development of raltegravir (MK-0518; Isentress)
and related HIV integrase inhibitors.
Laufer R, Gonzalez Paz O, Di Marco A, et al
Drug Metab Dispos.
2009 Jan 14.
Abstract
-
The G140S mutation in HIV integrases from raltegravir-resistant
patients rescues catalytic defect
due to the resistance Q148H mutation.
Delelis O, Malet I, Na L,
et al
Nucleic Acids Res.
2009 Jan 7
Abstract
-
Role of the new molecules in antiretroviral therapy. Position of
raltegravir
Arribas JR.
Enferm Infecc Microbiol Clin.
2008 Nov;26 Suppl 12:53-9 -
A WEEK IN REVIEW FEATURED REPORT
Raltegravir susceptibility and fitness progression of HIV type-1
integrase in patients on
long-term antiretroviral therapy.
Buzón MJ, Marfil S, Puertas MC,
et al
Antivir Ther.
2008;13(7):881-93.
Abstract
-
Raltegravir: The first HIV integrase inhibitor.
Cocohoba J, Dong BJ.
Clin Ther. 2008
Oct;30(10):1747-65
Abstract
-
A WEEK IN REVIEW FEATURED
REPORT
Discovery of Raltegravir, a Potent, Selective Orally
Bioavailable HIV-Integrase Inhibitor for the Treatment
of
HIV-AIDS
Infection.
Summa V, Petrocchi A, Bonelli F, et al
J Med Chem. 2008 Sep 3.
Abstract
-
HIV-2 integrase gene polymorphism and phenotypic
susceptibility of HIV-2 clinical isolates to the integrase
inhibitors
raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, et al
J Antimicrob
Chemother. 2008 Aug 20.
Abstract
-
FULL-TEXT ARTICLE
Raltegravir: first in class HIV integrase inhibitor.
Temesgen Z, Siraj DS.
Ther Clin Risk Manag. 2008 Apr;4(2):493-500.
Abstract
-
A WEEK IN REVIEW FEATURED REPORT
Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT, Cooper DA, Kumar PN, et al
N Engl J Med. 2008 Jul
24;359(4):339-54.
Abstract
-
Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir
Does Not
Prolong the QTcF Interval.
Iwamoto M, Kost JT, Mistry GC, et al
J Clin Pharmacol. 2008 Apr 25
Abstract
-
A WEEK IN REVIEW FEATURED REPORT
Raltegravir: an integrase inhibitor for HIV-1.
Evering TH, Markowitz M.
Expert Opin Investig Drugs. 2008 Mar;17(3):413-22.
Abstract
-
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay
kinetics of HIV,
significantly reducing the second phase.
Murray JM, Emery S, Kelleher AD, et al
AIDS. 2007 Nov 12;21(17):2315-21.
Abstract -
Raltegravir (MK-0518): a novel integrase
inhibitor for the treatment of HIV infection.
Anker M, Corales RB.
Expert Opin Investig Drugs.
2008 Jan;17(1):97-103.
Abstract-
A WEEK-IN-REVIEW FEATURED REPORT
Metabolism and Disposition in Humans of Raltegravir
(MK-0518), an Anti-AIDS Drug Targeting
the
HIV-1 Integrase Enzyme.
Kassahun K, McIntosh I, Cui D, et al
Drug Metab Dispos. 2007 Jun 25;
Abstract
|
-
Pharmacokinetics and Pharmacodynamics of Once-Daily
Versus Twice-Daily Raltegravir in Treatment-Naive
HIV-Infected Patients.
Rizk ML, Hang Y, Luo WL,
et al
Antimicrob Agents Chemother.
2012 Mar 19.
Abstract
Population Pharmacokinetic Analysis and Pharmacogenetics of
Raltegravir In HIV-positive a
nd Healthy Individuals.
Arab-Alameddine M, Fayet-Mello A, Lubomirov R,
et al
Antimicrob Agents Chemother.
2012 Feb 27
Abstract
-
Pharmacokinetic and short-term virologic response of low dose raltegravir
400mg once daily maintenance
therapy.
Ananworanich J, Gorowara M, Avihingsanon A, et al
Antimicrob Agents Chemother.
2012 Jan 17
Abstract
-
Inter- and intra-patient variability of raltegravir
pharmacokinetics in HIV-1-infected subjects.
Cattaneo D, Gervasoni C, Meraviglia P,
et al
J Antimicrob Chemother. 2011 Nov 29
Abstract
-
Pharmacokinetic Effects of Co-Administration of Lersivirine with Raltegravir
or Maraviroc
in Healthy Subjects.
Vourvahis M, Langdon G, Labadie RR, et al
Antimicrob Agents Chemother. 2011 Nov
28
Abstract
-
Pharmacokinetic Modeling of Plasma and Intracellular
Concentrations of Raltegravir in Healthy Volunteers.
Wang L, Soon GH, Seng KY,
et al
Antimicrob Agents Chemother.
2011 Jul 11
Abstract
-
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Calcagno A, Nozza S, Bonora S,
et
al
J Antimicrob Chemother.
2011 Jun 4
Abstract
-
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in
treatment experienced
patients.
Barrail-Tran A, Yazdanpanah Y, Goldwirt L, et al
AIDS.
2010 Oct 23;24(16):2581-3.
Abstract
-
Effect of Antacids on the Pharmacokinetics of Raltegravir in Human
Immunodeficiency Virus
Seronegative Volunteers.
Kiser JJ, Bumpass JB, Meditz AL, et al
Antimicrob Agents Chemother.
2010 Oct 4.
Abstract
-
Pharmacokinetics and Pharmacogenomics of Once Daily Raltegravir and
Atazanavir in
Healthy Volunteers.
Neely M, Decosterd L, Fayet A, et al
Antimicrob Agents Chemother. 2010 Sep
Abstract
-
Raltegravir: a review of its pharmacokinetics,
pharmacology and clinical studies.
Burger DM.
Expert Opin Drug Metab Toxicol.
2010 Aug 12.
Abstract
-
Assessment of the pharmacokinetics of co-administered
maraviroc and raltegravir.
Andrews E, Glue P, Fang J,
et al
Br J Clin Pharmacol.
2010 Jan;69(1):51-57.
Abstract
-
Pharmacokinetics of Raltegravir in Individuals With UGT1A1
Polymorphisms.
Wenning L, Petry A, Kost J, et al
Clin Pharmacol Ther.
2009 Mar 11
Abstract
-
Lack of a Clinically Important Effect of Moderate
Hepatic Insufficiency and Severe Renal Insufficiency on
Raltegravir Pharmacokinetics.
Iwamoto M, Hanley WD, Petry AS, et al
Antimicrob Agents Chemother.
2009 Feb 17
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Antiretroviral Activity, Pharmacokinetics, and Tolerability of
MK-0518, a Novel Inhibitor of
HIV-1 Integrase,
Dosed As Monotherapy for 10 Days in Treatment-Naive
HIV-1-Infected
Individuals.
Markowitz M, Morales-Ramirez JO, Nguyen BY, et al
J Acquir Immune Defic
Syndr. 2006 Dec 15;43(5):509-515.
Abstract
-
Pharmacokinetics and interactions of raltegravir
Placeres Alsina MM, Tuset Creus M, Miró JM.
Enferm Infecc Microbiol Clin.
2008 Nov;26 Suppl 12:23-
Abstract
-
A randomized study of pharmacokinetics, efficacy and
safety of two raltegravir plus atazanavir strategies in
ART-treated adults.
Carey D, Pett SL, Bloch M,
et al
J Acquir Immune Defic Syndr.
2012 Mar 14.
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in
Vertically HIV-Infected Children,
Adolescents
and Young Adults: A 60-Month Follow-Up Study.
Viganò A, Bedogni G, Manfredini V,
et al
Clin Drug Investig.
2011;31(6):407-15
Abstract
-
Long-Term Safety from the Raltegravir Clinical
Development Program.
Teppler H, Brown DD, Leavitt RY,
et
al
Curr HIV Res.
2011 Jan 3.
Abstract
-
Hepatic safety profile of raltegravir in HIV-infected
patients with chronic hepatitis C.
Vispo E, Mena A, Maida I, et al
J Antimicrob Chemother.
2009 Dec 23
Abstract
-
Raltegravir dosage adjustment in HIV-infected
patients receiving etravirine.
Do VT, Higginson RT, Fulco PP.
Am J Health Syst Pharm.
2011 Nov 1;68(21):2049-54
Abstract -
Pharmacokinetic Effects of Co-Administration of Lersivirine with
Raltegravir or Maraviroc
in Healthy Subjects.
Vourvahis M, Langdon G, Labadie RR, et al
Antimicrob Agents Chemother. 2011
Nov 28
Abstract -
Raltegravir dosage adjustment in HIV-infected patients
receiving etravirine.
Do VT, Higginson RT, Fulco PP.
Am J Health Syst Pharm. 2011 Nov 1
Abstract -
Effect of raltegravir on estradiol and norgestimate
plasma pharmacokinetics following oral contraceptive
administration in healthy women.
Anderson MS, Hanley WD, Moreau AR,
et
al
Br J Clin Pharmacol. 2011
Apr;71(4):616-20.
Abstract -
Pharmacokinetic and safety profile of raltegravir and
ribavirin, when dosed separately and together,
in healthy volunteers.
Ashby J, Garvey L, Erlwein OW,
et
al
J Antimicrob Chemother. 2011
Mar 15.
Abstract -
Pharmacokinetics and safety of the co-administration of
the antiretroviral raltegravir
and the lipid-lowering drug ezetimibe in healthy volunteers.
Jackson A, D'Avolio A, Watson V
et al
J Antimicrob Chemother. 2011
Apr;66(4):885-9.
Abstract -
A WEEK-IN-REVIEW FEATURED REPORT
Predictors of Clinically Significant Drug-Drug Interactions Among
Patients Treated with Nonnucleoside
Reverse Transcriptase Inhibitor-, Protease Inhibitor-, and
Raltegravir-Based Antiretroviral Regimens (March).
Patel N, Abdelsayed S, Veve M, Miller CD.
Ann Pharmacother. 2011 Mar 8.
Abstract -
Raltegravir is a substrate for SLC22A6: A putative
mechanism for the interaction between
raltegravir and tenofovir.
Moss DM, Kwan WS, Liptrott NJ,
et al
Antimicrob Agents Chemother.
2010 Nov
Abstract -
Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on
Raltegravir:
In Vitro/In Vivo Correlation.
Brainard DM, Kassahun K, Wenning LA, et al
J Clin Pharmacol.
2010 Sep 17.
Abstract -
A WEEK-IN REVIEW FEATURED REPORT
Daily dosing of tacrolimus in patients treated with HIV-1 therapy
containing a
ritonavir-boosted protease inhibitor or raltegravir.
Bickel M, Anadol E, Vogel M, et al
J Antimicrob Chemother.
2010 Mar
Abstract -
Assessment of the pharmacokinetics of co-administered
maraviroc and raltegravir.
Andrews E, Glue P, Fang J,
et al
Br J Clin Pharmacol.
2010 Jan;69(1):51-57.
Abstract -
Effect of Rifampin, a Potent Inducer of Drug
Metabolizing Enzymes, on the
Pharmacokinetics of Raltegravir.
Wenning LA, Hanley WD, Brainard DM, et
al
Antimicrob Agents Chemother. 2009 May 11-13
Abstract -
Effect of Tipranavir + Ritonavir on Pharmacokinetics of Raltegravir.
Hanley WD, Wenning LA, Moreau A
Antimicrob Agents Chemother.
2009 Apr 27
Abstract -
Effects of Omeprazole on Plasma Levels of Raltegravir.
Iwamoto M, Wenning LA,
Nguyen BY, et al
Clin Infect Dis. 2009 Jan 1.
Abstract-
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of
Raltegravir.
Iwamoto M, Wenning LA, Petry AS, et al
Antimicrob Agents Chemother. 2008 Oct 6
Abstract-
Minimal Pharmacokinetic Interaction Between the HIV Non-Nucleoside
Reverse Transcriptase Inhibitor
Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects.
Anderson MS, Kakuda TN, Hanley W, et al
Antimicrob Agents Chemother. 2008 Oct 6.
Abstract-
Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA, Friedman EJ, Kost JT, et al
Antimicrob Agents Chemother. 2008 Jul 14.
Abstract -
Atazanavir modestly increases plasma levels of raltegravir in
healthy subjects.
Iwamoto M, Wenning LA, Mistry GC, et al
Clin Infect Dis. 2008 Jul 1;47(1):137-40
Abstract-
Lack of a pharmacokinetic effect of raltegravir on midazolam: in
vitro/in vivo correlation.
Iwamoto M, Kassahun K, Troyer MD, et al
J Clin Pharmacol. 2008 Feb;48(2):209-14.
Abstract
-
A randomized study of pharmacokinetics, efficacy and safety
of two raltegravir plus atazanavir strategies
in ART-treated adults.
Carey D, Pett SL, Bloch M,
et al
J Acquir Immune Defic Syndr.
2012 Mar 14.
Abstract
-
Impaired maraviroc and raltegravir clearance in a human
immunodeficiency virus-infected patient with end-stage
liver
disease and renal impairment: a management dilemma.
Pau AK, Penzak SR, Boyd SD, et
al
Pharmacotherapy.
2012 Jan;32(1):
Abstract
-
A WEEK-IN REVIEW FEATURED REPORT
Potent and Sustained Antiviral Response of Raltegravir-based Highly
Active Antiretroviral Therapy in
HIV Type 1-infected Children and Adolescents.
Briz V, León-Leal JA, Palladino C,
et
al
Pediatr Infect Dis J.
2012 Mar;31(3):273-277.
Abstract
-
A WEEK-IN REVIEW FEATURED REPORT
Long-term Efficacy and Safety of Raltegravir, Etravirine, and
Darunavir/Ritonavir in
Treatment-Experienced Patients: Week 96 Results from the ANRS 139 TRIO
Trial.
Fagard C, Colin C, Charpentier C, et al
J Acquir Immune Defic Syndr.
2012 Jan 30
Abstract
-
Raltegravir, Tenofovir DF, and Emtricitabine for
Post-Exposure Prophylaxis to Prevent
the Sexual Transmission ofO
HIV: Safety, Tolerability, and Adherence.
Mayer KH, Mimiaga MJ, Gelman M, Grasso C.
J Acquir Immune Defic Syndr.
2012 Jan 19
Abstract
-
Raltegravir in HIV-1 infection: Safety and Efficacy in
Treatment-naïve Patients.
Pandey KK.
Clin Med Rev Ther.
2011 Dec 20;2012(4):13-30.
Abstract
-
Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing
Regimens (R+M+) versus
Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M-).
Antoniou T, Smith G, Su D, et al
J Int Assoc Physicians AIDS Care (Chic
Abstract
-
Successful tacrolimus treatment following renal
transplant in a HIV-infected patient with raltegravir previously
treated with a protease inhibitor based regimen.
Cousins D, Topping K, Lee V, et al
Drug Metabol Drug Interact.
2011;26(3):139-41.
Abstract
-
Raltegravir in a special case - Patient with HIV and
Burkitt's lymphoma
Bieniek B.
Dtsch Med Wochenschr.
2011 Oct;136(41):2091-3.
Abstract
-
Long-term Treatment With Raltegravir or Efavirenz Combined With
Tenofovir/Emtricitabine
for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients:
156-Week Results From STARTMRK.
Rockstroh JK, Lennox JL,
Dejesus E,
et
al
Clin Infect Dis. 2011
Oct;53(8):807-816.
Abstract
-
Role of raltegravir in the management of HIV-1
infection.
Okeke NL, Hicks C.
HIV AIDS (Auckl). 2011;3:81-92.
Abstract
-
Similar efficacy of raltegravir when used with or without a protease
inhibitor in treatment-experienced patients.
Skiest DJ, Cohen C, Mounzer K, et al
HIV Clin Trials.
2011 May-Jun;12(3):131-40.
Abstract
-
Efficacy and safety of raltegravir in
treatment-experienced HIV-1-infected patients switching from
enfuvirtide-based
regimens: 48 week results of the randomized EASIER
ANRS 138 trial.
Gallien S, Braun J, Delaugerre C, Charreau I, et al
J Antimicrob Chemother. 2011
Jun 28.
Abstract
-
Similar efficacy of raltegravir when used with or without a protease
inhibitor in treatment-experienced
patients.
Skiest DJ, Cohen C, Mounzer K,
et al
HIV Clin Trials. 2011
May-Jun;12(3):131-40.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Safety and efficacy of raltegravir in patients with HIV-1 and
hepatitis B and/or C
virus coinfection.
Rockstroh J, Teppler H, Zhao J, et al
HIV Med. 2011
May 22.
Abstract
-
Clinical Efficacy of Raltegravir Against B and Non-B
Subtype HIV-1 in the STARTMRK and BENCHMRK Studies.
Rockstroh JK, Teppler H, Zhao J, et al
AIDS. 2010 Apr 25
Abstract
-
Use of Maraviroc-, Raltegravir-, and Etravirine-Containing Regimens in
Treatment-Experienced Patients:
A Case-Series Study.
Youngblood C, Sayana S, Khanlou H.
J Int Assoc Physicians AIDS Care (Chic).
2011 Mar 23
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Raltegravir and unboosted atazanavir dual therapy in
virologically suppressed antiretroviral
treatment-experienced HIV patients.
Cordery DV, Hesse K, Amin
J, Cooper DA.
Antivir
Ther. 2010;15(7):1035-8
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Optimal
use of raltegravir (Isentress(R)) in the treatment of HIV-infected
adults -
Canadian consensus guidelines.
Rachlis A, Angel JB, Harris M, et al
Can J Infect Dis Med Microbiol.
2009 Fall;20(3):e67-80.
Paper -
Long-term successful control of super-multidrug-resistant human
immunodeficiency
virus type 1 infection by a novel combination therapy of raltegravir,
etravirine, and
boosted-darunavir.
Nakamura H, Miyazaki N, Hosoya N, et al
J Infect Chemother. 2010 Jun
30
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Raltegravir Versus Efavirenz Regimens in Treatment-Naive
HIV-1-Infected Patients:
96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic
Analyses.
Lennox JL, Dejesus E, Berger DS, et al
J Acquir Immune Defic Syndr.
2010 Apr 15
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Raltegravir Plasma Concentrations in Treatment-Experienced Patients
Receiving Salvage
Regimens Based on Raltegravir With and Without Maraviroc
Coadministration (May).
Baroncelli S, Villani PA, Weimer LE,
et al
Ann Pharmacother. 2010 Apr 6
Abstract
-
A WEEK-IN-REVIEW
FEATURED REPORT
Raltegravir: In Treatment-Naive Patients with HIV-1
Infection.
Croxtall JD, Scott LJ.
Drugs.
2010 Mar 26;70(5):631-42.
Abstract
-
A WEEK-IN REVIEW FEATURED REPORT
Long-Term Efficacy and Safety of Raltegravir Combined with Optimized
Background
Therapy in Treatment-Experienced Patients with Drug-Resistant HIV
Infection:
Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials.
Steigbigel RT, Cooper DA, Teppler H, et al
Clin Infect Dis.
2010 Jan 19
Abstract
-
A WEEK-IN-REVIEW
FEATURED REPORT
Raltegravir: is a 400 mg once-daily dose enough?
Lanzafarme M, Hill A, Lattuada E,
et al
J Antimicrob Chemother. 2010 Jan 12
Abstract
-
A WEEK-IN REVIEW FEATURED REPORT
A new drug combination therapy for treatment-naive patients with HIV-1
infection,
consisting of raltegravir, emtricitabine and tenofovir disoproxil
fumarate
Clercq ED.
Expert Opin Pharmacother.
2009 Dec;10
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Switch from enfuvirtide to raltegravir in virologically suppressed
HIV-1 infected patients:
Effects on level of residual viremia and quality of life.
Grant PM, Palmer S, Bendavid E, et al
J Clin Virol.
2009 Oct 8.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
High Rate of Virologic Suppression with Raltegravir Plus Etravirine
and Darunavir/Ritonavir
among Treatment-Experienced Patients Infected with Multidrug-Resistant
HIV: Results of
the ANRS 139 TRIO Trial.
Yazdanpanah Y, Fagard C, Descamps D, et al
Clin Infect Dis.
2009 Oct 8.
Abstract
-
Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of
Combination Therapy in
Treatment-Naive Patients With HIV-1 Infection.
Markowitz M, Nguyen BY, Gotuzzo E, et al
J Acquir Immune Defic Syndr.
2009 Jul 30
Abstract
-
Safety and efficacy of raltegravir-based versus efavirenz-based
combination therapy in
treatment-naive patients with HIV-1 infection: a multicentre,
double-blind randomised
controlled trial.
Lennox JL, Dejesus E, Lazzarin A, et al
Lancet. 2009 Jul 31.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients
Cotreated
with Immunosuppressive Drugs.
Tricot L, Teicher E, Peytavin G, et al
Am J Transplant.
2009 Jun 10.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Raltegravir: A Review of its Use in the Management of
HIV Infection in Treatment-Experienced
Patients.
Croxtall JD, Keam SJ.
Drugs. 2009 Jun
4;69(8):1059
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Treatment of HIV infection with raltegravir.
Chirch LM, Morrison S, Steigbigel RT
Expert Opin Pharmacother.
2009 Apr 22
Abstract
-
Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in
Antiretroviral Treatment-Experienced
Participants.
Gupta S, Lataillade M, Farber S, Kozal MJ.
J Int Assoc Physicians AIDS Car. 2009 Mar 6.
Abstract
-
Efficacy of raltegravir: from healthy volunteers to phase III
trials
Gatell JM.
Enferm Infecc Microbiol Clin.
2008 Nov;26 Suppl 12:29-33
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor
Raltegravir as Part of
Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of
a 48-Week
Controlled Study.
Markowitz M, Nguyen BY, Gotuzzo E, et al
J Acquir Immune Defic Syndr.
2007 Aug 23
Abstract
-
Safety and efficacy of the HIV-1 integrase inhibitor
raltegravir (MK-0518) in treatment-
experienced patients with multidrug-resistant virus: a
phase II randomised controlled trial.
Grinsztejn B, Nguyen BY, Katlama C, et al
Lancet. 2007 Apr 14;369(9569):1261-9.
Abstract
|
|
|
-
A sensitive liquid chromatography coupled with mass spectrometry method for the
intracellular and plasma
quantification of raltegravir after solid-phase extraction.
Mosnier-Thoumas S, Djabarouti S, Xuereb F, et al
J Pharm Pharmacol. 2011
Dec;63(12):1559-65.
Abstract
-
Clinical evaluation of the determination of plasma
concentrations of darunavir, etravirine,
raltegravir and ritonavir in dried blood spot samples.
Ter Heine R, Mulder JW, van Gorp EC, et
al
Bioanalysis. 2011
May;3(10):1093-7
Abstract
-
Limited Sampling Strategies for the Estimation of Raltegravir
Daily Exposure in HIV-Infected Patients.
Cattaneo D, Ripamonti D, Gervasoni C,
et al
J Clin Pharmacol. 2011 Mar 7.
Abstract
-
Simultaneous determination of raltegravir and
raltegravir glucuronide in human plasma by liquid
chromatography-tandem mass spectrometric method.
Wang LZ, Lee LS, Thuya WL, et al
J Mass Spectrom. 2011 Jan
24:202-208.
Abstract
-
Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract
secretions
using high-performance liquid chromatography with ultraviolet detection.
Talameh JA, Rezk NL, Kashuba AD.
J Chromatogr B Analyt Technol Biomed Life Sci.
2009 Nov 13
Abstract
-
Lack of specificity for the analysis of raltegravir using online sample
clean-up liquid
chromatography-electrospray
tandem mass spectrometry.
Jourdil JF, Bartoli M, Stanke-Labesque F., et al
J
Chromatogr B Analyt Technol Biomed Life Sci.
2009 Aug 27
Abstract
-
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral
agents: Raltegravir,
maraviroc, darunavir, and etravirine.
Fayet A, Béguin A, Zanolari B, Cruchon S, et al
J Chromatogr B Analyt Technol Biomed Life Sci.
2009 Feb 28
Abstract
-
Simultaneous determination of maraviroc and raltegravir in human
plasma by HPLC-UV.
Notari S, Tommasi C, Nicastri E, et al
IUBMB Life.
2009 Mar 24;61(4):470-475
Abstract
-
Quantification of the HIV-integrase inhibitor raltegravir and detection of its
main metabolite
in human plasma,
dried blood spots and peripheral blood mononuclear cell lysate by means of
high-performance liquid
chromatography tandem mass spectrometry.
Ter Heine R, Hillebrand MJ, Rosing H, et al
J Pharm Biomed Anal. 2008
Nov 27.
Abstract
-
An accurate and precise high-performance liquid chromatography method for
the rapid
quantification of the novel
HIV integrase inhibitor raltegravir in human blood plasma after solid
phase
extraction.
Rezk NL, White N, Kashuba AD, et al
Anal Chim Acta. 2008 Nov 3;628(2):204-13
Abstract
-
A sensitive HPLC-MS-MS method for the determination of
raltegravir in human plasma.
Long MC, Bennetto-Hood C, Acosta EP.
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Apr
1
Abstract -
Quantification of the HIV-integrase inhibitor raltegravir
(MK-0518) in human plasma by
high-performance liquid chromatography with fluorescence
detection.
Poirier JM, Robidou P, Jaillon P.
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Apr
4
Abstract
-
Determination of the HIV integrase inhibitor, MK-0518
(raltegravir), in human plasma using
96-well liquid-liquid extraction and HPLC-MS/MS.
Merschman SA, Vallano PT, Wenning LA, et al
J Chromatogr B Analyt Technol Biomed Life Sci.
2007 Jul 5;
Abstract
|
-
In-vivo Selection of the Mutation F121Y in a Patient
Failing Raltegravir Containing Salvage Regimen.
Cavalcanti JD, Lança AM, Ferreira JL,
et al
Antiviral Res. 2012 May 4.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected
Patients Failing on
Raltegravir-Containing Regimens.
Garrido C, Villacian J, Zahonero N, et al
Antimicrob Agents Chemother.
2012 Mar 26
Abstract
-
Analyses of transmitted resistance and selective pressure
in HIV-1 naive patients to Raltegravir and failure HAART in Sao Paulo,
Brazil.
Mantovani NP, Azevedo RG, Rabelato JT, et al
J Clin Microbiol. 2012 Mar 7
Abstract
-
Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations
During Raltegravir Treatment:
A Refined Analysis by Ultra-Deep 454 Pyrosequencing.
Armenia D, Vandenbroucke I, Fabeni L, et al
J Infect Dis. 2012 Jan 11.
Abstract
-
In vitro resistance selections using elvitegravir, raltegravir, and
two metabolites of elvitegravir
M1 and M4.
Margot NA, Hluhanich RM, Jones GS, et al
Antiviral Res. 2011
Dec 16.
Abstract
-
Long-lasting persistence of integrase resistance mutations in
HIV-2-infected patients
after raltegravir withdrawal.
Charpentier C, Larrouy L, Matheron S,
et al
Antivir Ther. 2011;16(6):937-940.
Abstract
-
MK-0536 inhibits HIV-1 integrases resistant to
raltegravir.
Métifiot M, Johnson B, Smith S,
et
al
Antimicrob Agents Chemother.
2011 Aug 29.
Abstract
-
Switching between raltegravir resistance pathways analyzed
by deep sequencing.
Mukherjee R, Jensen ST, Male F,
et al
AIDS. 2011 Aug 9.
Abstract
-
Resistance to raltegravir highlights integrase mutations at
codon 148 in conferring
cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O, Van Ginderen M, Vos A, et al
Antiviral Res. 2011
Jun 12;91(2):167-176.
Abstract
-
Single Mutations in HIV Integrase Confer High-Level
Resistance to Raltegravir in Primary Human Macrophages.
Marsden MD, Avancena P, Kitchen CM,
et
al
Antimicrob Agents Chemother. 2011
May 31.
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Elvitegravir overcomes resistance to raltegravir induced by
integrase mutation Y143.
Métifiot M, Vandegraaff N, Maddali K, et al
AIDS. 2011 Apr 18.
Abstract
-
The SnoB study: frequency of baseline raltegravir
resistance mutations prevalence in different non-B subtypes.
Sierra S, Lübke N, Walter H, et al
Med Microbiol Immunol. 2011 Apr 8
Abstract
-
Transmission of integrase strand-transfer inhibitor
multidrug-resistant HIV-1: case report and response to
raltegravir-containing antiretroviral therapy.
Young B, Fransen S, Greenberg KS, Thomas A, et al
Antivir Ther. 2011;16(2):253-6.
Abstract
-
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected
patient.
Boyd SD, Maldarelli F, Sereti I,
et al
Antivir Ther.
2011;16(2):257-61.
Abstract
-
Plasma raltegravir exposure influences the antiviral
activity and selection of resistance mutations.
Garrido C, de Mendoza C, Alvarez E, et al
AIDS Res Hum Retroviruses. 2011
Apr 3
Abstract
-
Prevalence of resistance mutations related to integrase
inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated
patients.
Malet I, Wirden M, Fourati S,
et al
J Antimicrob Chemother.
2011 Apr 7
Abstract
-
Emerging integrase inhibitor resistance mutations in raltegravir-treated
HIV-1-infected patients
with low-level viremia.
Gallien S, Delaugerre C, Charreau I, et al.
AIDS. 2011 Feb 14
Abstract
-
Emergence of raltegravir-resistant HIV-1 in the central
nervous system.
Watanabe K, Honda M, Watanabe T, et al
Int J STD AIDS.
2010 Dec;21(12):840-1.
Abstract
-
Hot spots of integrase genotypic changes leading to HIV-2
resistance to raltegravir.
Charpentier C, Roquebert B, Delelis O, et al
Antimicrob Agents Chemother.
2010 Dec 28.
Abstract
-
Analysis of low frequency mutations associated with drug-resistance to
raltegravir before
antiretroviral treatment.
Liu J, Miller MD, Danovich RM,
et al
Antimicrob Agents Chemother.
2010 Dec 20
Abstract
-
Genetic barrier to antiretroviral drug-resistance. Focus on
raltegravir, the first integrase inhibitor
Delaugerre C.
Med Mal Infect. 2010 Sep;40 Suppl
1:S1-10.
Abstract
-
A WEEK-IN-REVIEW
FEATURED REPORT
Resistance analyses in highly experienced patients failing
raltegravir, etravirine
and darunavir/ritonavir regimen.
Charpentier C, Roquebert B, Colin C, et al
AIDS. 2010 Aug 26
Abstract
-
Discovery of potent HIV integrase inhibitors active against
raltegravir resistant viruses.
Le G, Vandegraaff N, Rhodes DI, et al
Bioorg Med Chem Lett. 2010 Jul 16.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Effect of Raltegravir Resistance Mutations in HIV-1
Integrase on Viral Fitness.
Hu Z, Kuritzkes DR.
J Acquir Immune Defic Syndr.
2010 Jul 14
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
The HIV-1 integrase mutations Y143C/R are an alternative pathway for
resistance
to Raltegravir and impact the enzyme functions.
Reigadas S, Anies G, Masquelier B, et al
PLoS One.
2010 Apr 26;5(4):e10311.
Paper
-
Primary mutations selected in vitro with raltegravir confer large fold
changes
in susceptibility to first-generation integrase inhibitors, but minor fold
changes
to inhibitors with second-generation resistance profiles.
Goethals O, Vos A, Van Ginderen M, . et al
Virology.
2010 Apr 24.
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
HIV-1 resistance patterns to integrase inhibitors in
antiretroviral-experienced patients with
virological failure on raltegravir-containing regimens.
da Silva D, Van Wesenbeeck L, Breilh D,
et al
J Antimicrob Chemother.
2010 Apr 12
Abstract
-
Biochemical and Pharmacological Analyses of HIV-1 Integrase
Flexible Loop Mutants
Resistant To Raltegravir.
Métifiot M, Maddali K, Naumova A, Zhang X, et al.
Biochemistry. 2010 Mar 24.
Abstract
-
Raltegravir as functional monotherapy leads to virological failure and
drug
resistance in highly treatment-experienced HIV-infected patients.
Caby F, Valin N, Marcelin AG, Schneider L, et al
Scand J Infect Dis.
2010 Mar 12.
Abstract
-
The HIV-1 integrase genotype strongly predicts
raltegravir susceptibility but
not viral fitness of primary virus
isolates.
Buzón MJ, Dalmau J, Puertas MC, et al
AIDS.
2010 Jan 2;24(1):17-25.
Abstract
-
A WEEK-IN REVIEW FEATURED REPORT
Early emergence of raltegravir resistance mutations in patients receiving
HAART
salvage regimens.
Baldanti F, Paolucci S, Gulminetti R, et al
J Med Virol. 2009 Nov
30;82(1):116-122.
Abstract
-
Panel of Prototypical Raltegravir-Resistant Infectious Molecular Clones in
a Novel Integrase-Deleted
Cloning Vector.
Reuman EC, Bachmann MH, Varghese V, et al
Antimicrob Agents Chemother. 2009
Nov 16.
Abstract
-
Raltegravir has no residual antiviral activity in vivo against HIV-1
with
resistance-associated
mutations to this drug.
Wirden M, Simon A, Schneider L,
et al
J Antimicrob Chemother. 2009 Aug 27
Abstract
-
HIV-1 IN alternative molecular recognition of DNA induced
by raltegravir resistance mutations.
Mouscadet JF, Arora R, André J, et al
J Mol Recognit.
2009 Jul 21.
Abstract
-
Dynamics of Raltegravir Resistance Profile in an HIV Type 2-Infected Patient.
Xu L, Anderson J, Garrett N, et al
AIDS Res Hum Retroviruses.
2009 Jul 20.
Abstract
-
A WEEK IN REVIEW FEATURED REPORT
Evolution of raltegravir resistance during therapy.
Sichtig N, Sierra S, Kaiser R, et al
J Antimicrob Chemother.
2009 May 14.
Abstract
-
Genetic barriers for integrase inhibitor
drug resistance in HIV type-1 B and CRF02_AG subtypes.
Maïga AI, Malet I, Soulie C,
et al
Antivir Ther.
2009;14(1):123-
Abstract
-
Quasispecies variant dynamics during
emergence of resistance to raltegravir in HIV-1-infected
patients.
Malet I, Delelis O, Soulie C, Wirden M, et al
J Antimicrob Chemother. 2009 Feb 16
Abstract
-
A WEEK IN REVIEW FEATURED REPORT
Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic
Reactions and on a Series of
Drug-Resistant Integrase Mutants.
Marinello J, Marchand C, Mott BT, et al
Biochemistry. 2008 Aug 15.
Abstract-
Genetic diversity of integrase (IN) sequences in
antiretroviral treatment-naive and
treatment-experienced
HIV type 2 patients.
Xu L, Anderson J, Ferns B, et al
AIDS Res Hum Retroviruses. 2008 Jul;24(7):1003-7.
Abstract-
Drug resistance profiles for the HIV integrase gene in
patients failing raltegravir salvage therapy.
Charpentier C, Karmochkine M, Laureillard D, et al
HIV Med. 2008 Jul 21.
Abstract-
Subgroup and resistance analyses of raltegravir for
resistant HIV-1 infection.
Cooper DA, Steigbigel RT, Gatell JM, et al
N Engl J Med. 2008 Jul 24;359(4):355-65.
Abstract- A WEEK IN REVIEW FEATURED REPORT
Mutations Associated with Failure of
Raltegravir Treatment affect integrase sensitivity to
the inhibitor in vitro.
Malet I, Delelis O, Valantin MA, et al
Antimicrob Agents Chemother. 2008 Jan 28
Abstract
|
-
A WEEK-IN-REVIEW FEATURED REPORT
Body Composition Changes after Switching from Protease
Inhibitors to Raltegravir: SPIRAL-LIP substudy.
Curran A, Martinez E, Saumoy M, et al
AIDS. 2011 Nov
22.
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Development of Buffalo Hump in the course of antiretroviral therapy
including raltegravir and unboosted
atazanavir: a case report and review of the literature.
Ceccarelli G, d'Ettorre G,
Marchetti F, et al
J Med Case Reports. 2011 Feb 17;5(1):70
Abstract
-
Severe raltegravir-associated rhabdomyolysis: a case
report and review of the literature.
Croce F, Vitello P, Dalla Pria A, et al
Int J STD AIDS. 2010
Nov;21(11):783-5.
Abstract
-
Early onset of autoimmune disease by the retroviral
integrase inhibitor raltegravir.
Beck-Engeser GB, Eilat D, Harrer T,
et al
Proc Natl Acad Sci U S A.
2009 Nov 18.
Abstract
|
-
FULL-TEXT ARTICLE
Switching Virally Suppressed, Treatment-Experienced Patients
to a Raltegravir-Containing Regimen
Does Not Alter Levels of HIV-1 DNA.
Lam YM, McBride KL, Amin J,
et al
PLoS One.
2012;7(3):e31990.
Paper
-
Impaired maraviroc and raltegravir clearance in a human
immunodeficiency virus-infected patient with end-stage liver
disease and renal impairment: a management dilemma.
Pau AK, Penzak SR, Boyd SD, et
al
Pharmacotherapy.
2012 Jan;32(1):
Abstract
-
Acceptable plasma concentrations of raltegravir and etravirine when
administered by gastrostomy tube
in a patient with advanced multidrug-resistant human immunodeficiency
virus infection.
Sandkovsky U, Swindells S, Moore R,
et al
Pharmacotherapy. 2012
Feb;32(2):142-7.
Abstract
-
Mechanisms involved in CD4 gains in HIV-infected
patients switched to raltegravir.
Garrido C, Rallón N, Soriano V,
et al
AIDS. 2011 Dec
29.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Implications of integrase inhibitors for
HIV-infected transplantation recipients: Raltegravir and
dolutegravir
(S/GSK 1349572).
Waki K, Sugawara Y.
Biosci Trends. 2011
Oct;5(5):189-91.
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Effect of raltegravir intensification on HIV proviral DNA in
the blood and gut mucosa of men on long-term therapy:
a randomized control trial.
Chege D, Kovacs C, La Porte C, et al
AIDS. 2012 Jan
14;26(2):167-74.
Abstract
-
No Effect of Raltegravir Intensification on Viral
Replication Markers in the Blood of
HIV-1-infected Patients Receiving Antiretroviral Therapy.
Gandhi RT, Coombs RW, Chan ES,
et al
J Acquir Immune Defic Syndr.
2011 Nov 11
Abstract
-
Successful tacrolimus treatment following
renal transplant in a HIV-infected patient with raltegravir
previously
treated with a protease inhibitor based regimen.
Cousins D, Topping K, Lee V, et al
Drug Metabol Drug Interact.
2011;26(3):139-41.
Abstract
-
Intensification of Antiretroviral Therapy With
Raltegravir or Addition of Hyperimmune Bovine Colostrum in
HIV-Infected
Patients With Suboptimal CD4+ T-Cell Response: A Randomized Controlled
Trial.
Byakwaga H, Kelly M, Purcell DF, et al
J Infect Dis. 2011
Sep 19.
Abstract
-
Treatment intensification with raltegravir in subjects with
sustained HIV-1 viraemia suppression:
a randomized 48-week study.
Llibre JM, Buzón MJ, Massanella M,
et al
Antivir Ther.
2011 Sep 28.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
A randomized cross-over study to compare raltegravir and efavirenz
(SWITCH-ER study).
Nguyen A, Calmy A, Delhumeau C, et al
AIDS.
2011 May 17
Abstract
-
Switch from Enfuvirtide to Raltegravir Lowers Plasma
Concentrations of Darunavir and Tipranavir:
a pharmacokinetic sub-study of the EASIER-ANRS 138 trial.
Goldwirt L, Braun J, de Castro N, et al
Antimicrob Agents Chemother.
2011 May 16
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in
Vertically HIV-Infected Children,
Adolescents
and Young Adults: A 60-Month Follow-Up Study.
Viganò A, Bedogni G, Manfredini V,
et al
Clin Drug Investig.
2011;31(6):407-15
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Raltegravir in patients at high vascular risk.
Olalla J, Del Arco A, de la Torre J,
et al
Med Clin (Barc).
2011 May 9.
Abstract
-
A Randomized, Controlled Trial of Raltegravir Intensification in
Antiretroviral-treated, HIV-infected Patients
with a Suboptimal CD4+ T Cell Response
Hatano H, Hayes TL, Dahl V,
et al
J Infect Dis. 2011
Apr;203(7):960-
Abstract
-
Impact on Health-Related Quality of Life of a Switch From Enfuvirtide
to Raltegravir
Among Multidrug-Resistant HIV-1-Infected Patients: A Randomized
Open-Label Trial
(EASIER-ANRS 138).
Boulet T, Pavie J, Charreau I, Braun J,
et
al
HIV Clin Trials. 2010 Jan
1;11(5):283-293
Abstract
-
HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients
and in Triple-Class
Experienced Patients Subsequently Treated with Raltegravir.
Varghese V, Liu TF, Rhee SY,
et al
AIDS Res Hum Retroviruses.
2010 Oct 21
Abstract
-
Clinical, virological and immunological responses in
Danish HIV patients receiving raltegravir
as part of a salvage regimen.
Engsig FN, Gerstoft J, Kronborg G, et al
Clin Epidemiol. 2010 Aug
9;2:145-51
Abstract
-
Effect of raltegravir-containing intensification on HIV burden and
T-cell activation in
multiple gut sites of HIV-positive adults on suppressive
antiretroviral therapy.
Yukl SA, Shergill AK, McQuaid K, et al
AIDS. 2010 Sep 4.
Abstract
-
Substitution of raltegravir for ritonavir-boosted protease inhibitors
in HIV-infected patients:
the SPIRAL study.
Martínez E, Larrousse M, Llibre JM, et al
AIDS. 2010 Jul 17;24(11):1697-707
Abstract
-
Prevention of HIV protease inhibitor-induced dysregulation of hepatic
lipid metabolism by
raltegravir via endoplasmic reticulum stress signaling pathways.
Cao R, Hu Y, Wang Y, Gurley EC, et al
J Pharmacol Exp Ther. 2010 Aug;334(2):530-9.
Abstract
-
Minimal removal of raltegravir by hemodialysis in HIV-infected
patients with
end stage renal disease.
Moltó J, Sanz-Moreno J, Valle M, et al
Antimicrob Agents Chemother.
2010 May
Abstract
-
HIV-1 replication and immune dynamics are affected by raltegravir
intensification
of HAART-suppressed subjects.
J Buzón M, Massanella M, Llibre JM, et al
Nat Med.
2010 Mar 14.
Abstract
-
Clinical outcome in resistant HIV-2 infection treated with
raltegravir and maraviroc.
Armstrong-James D, Stebbing J,
Scourfield A, et al
Antiviral Res.
2010 Mar 4.
Abstract
-
A WEEK-IN-REVIEW
FEATURED REPORT
Raltegravir, maraviroc, etravirine: an effective protease inhibitor
and nucleoside
reverse transcriptase inhibitor-sparing regimen for salvage therapy in
HIV-infected
patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A, et al
AIDS. 2010 Feb 11
Abstract
-
Raltegravir-based HAART regimen in a patient with large
B-cell lymphoma.
Fulco PP, Hynicka L, Rackley D.
Ann Pharmacother.
2010 Feb;44(2):377-82.
Abstract
-
Efficacy and safety of switching from enfuvirtide to
raltegravir in patients with virological suppression.
Santos JR, Llibre JM, Ferrer E, et al
HIV
Clin Trials. 2009 Nov-Dec;10(6):432-8.
Abstract
-
A WEEK-IN-REVIEW
FEATURED REPORT
Switch to a raltegravir-based regimen versus continuation of a
lopinavir-ritonavir-based
regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK
1 and 2): two multicentre, double-blind, randomised controlled trials
Eron JJ, Young B, Cooper DA, et al
Lancet.
2010 Jan 12.
Abstract
-
Raltegravir-Based HAART Regimen in a Patient with Large B-Cell
Lymphoma
(February).
Fulco PP, Hynicka L, Rackley D.
Ann Pharmacother.
2009 Dec 29.
Abstract
-
A WEEK IN REVIEW FEATURED REPORT
Switch from Enfuvirtide to Raltegravir in Virologically Suppressed
Multidrug-Resistant HIV-1-Infected
Patients: A Randomized Open-Label Trial.
De Castro N, Braun J, Charreau I,
et al
Clin Infect Dis.
2009 Sep 16.
Abstract
-
Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1
Patients Well Controlled on an
Enfuvirtide
Based Regimen: 24-Week Results of the CHEER Study.
Towner W, Klein D, Kerrigan HL,et a l
J Acquir Immune Defic Syndr.
2009 May 28.
Abstract
-
A WEEK-IN REVIEW FEATURED REPORT
Outcomes of multidrug-resistant patients switched from enfuvirtide to
raltegravir within a virologically suppressive
regimen.
Harris M, Larsen G, Montaner JS.
AIDS. 2008 Jun 19;22(10):1224-6.
Abstract
|
-
Raltegravir as functional monotherapy leads to virological failure and
drug
resistance in highly treatment-experienced HIV-infected patients.
Caby F, Valin N, Marcelin AG, Schneider L, et al
Scand J Infect Dis.
2010 Mar 12.
Abstract
-
Impaired
maraviroc and raltegravir clearance in a human
immunodeficiency virus-infected patient with
end-stage liver disease and renal impairment: a management
dilemma.
Pau AK, Penzak SR, Boyd SD, et al|
Pharmacotherapy.
2012 Jan;32(1):e1-6.
Abstract
-
Use of novel antiretroviral agents in rescue regimens:
A case of early virological failure to raltegravir.
Tommasi C, Ceccherini-Silberstein F, D'Arrigo R, et al
Scand J Infect Dis.
2010 Jan 19.
Abstract
-
Longitudinal analysis of raltegravir susceptibility and integrase
replication capacity
of HIV-1 during virologic failure.
Fransen S, Karmochkine M, Huang W
Antimicrob Agents Chemother. 2009 Aug 10.
Abstract
|
-
Intrapatient and Interpatient Pharmacokinetic
Variability of Raltegravir in the Clinical Setting.
Siccardi M, Dʼavolio A, Rodriguez-Novoa S, et al
Ther Drug Monit.
2012 Apr;34(2):232-235.
Abstract
-
Population Pharmacokinetic Analysis and Pharmacogenetics of
Raltegravir In HIV-positive a
nd Healthy Individuals.
Arab-Alameddine M, Fayet-Mello A, Lubomirov R,
et al
Antimicrob Agents Chemother.
2012 Feb 27
Abstract
-
Cost-effectiveness of Raltegravir in Antiretroviral
Treatment-Experienced HIV-1-Infected Patients
in Switzerland.
Elbasha, Szucs, Chaudhary, et al
HIV Clin Trials. 2009
Jul-Aug;10(4):233-53.
Abstract
-
Cost-Effectiveness Analysis of Raltegravir in Treatment-Experienced
HIV Type
1-Infected Patients in Spain.
Chaudhary MA, Moreno S, Kumar RN, et al
AIDS Res Hum Retroviruses.
2009 Jun 24.
Abstract
|
 |
|
Raltegravir Journal Citations |
|
Animal
Studies
Raltegravir
Main Page
Main
New/Newsworthy